Objectives: Hypertension and obesity are major public health issues. Both conditions are highly prevalent among African Americans and contribute to the increased burden of cardiovascular disease in this group. Inflammation is considered to be an underlying process in both conditions. The authors sought to determine if there is an interaction between high blood pressure (HBP) and obesity that is associated with markedly elevated plasma levels of proinflammatory cytokines in African American adults.
Introduction
Hypertension and obesity are major public health conditions that contribute to poor outcomes. Compared with whites, African Americans have a higher prevalence of both obesity [Hedley et al. 2004] and hypertension [Hajjar and Kotchen, 2003] and also have a greater prevalence and earlier onset of cardiovascular disease (CVD) [Hozawa et al. 2007 ]. Biomarkers of inflammation, particularly high sensitivity C-reactive protein (hsCRP), are predictive of greater risk for cardiovascular events ]. In humans, obesity is associated with accumulation of T cells and macrophages in adipose tissue, which may contribute to obesityrelated inflammation [Wu et al. 2007 ]. Elevations in plasma levels of proinflammatory cytokines, such as CRP and interleukin 6 (IL-6), are reported to be associated with obesity [Rocha and Libby, 2009; Lyon et al. 2003 ].
Reports also describe a link between inflammation and hypertension. Analysis of data from the Women's Health Study found that baseline CRP, was predictive of future risk of hypertension. However, other reports in humans indicate that CRP is a marker of established hypertension and CVD, rather than playing a causal role in the pathogenic process [Davey Smith et al. 2005] . Support for a causal role for inflammation in the pathogenesis of hypertensive vascular injury is based on data from basic experimental studies that focus on endothelial dysfunction and the renninangiotensinaldosterone system (RAAS). Exposure of human vascular endothelial cells to CRP in vitro results in decreased expression of endothelial nitric oxide synthase [Venugopal et al. 2002] . Alternatively, primary defects in the RAAS induce endothelial dysfunction and lead to increased endothelial cell expression of inflammatory cytokines [Schieffer et al. 2000; Vaughan et al. 1995] . Following angiotensin II exposure to bovine endothelial cells there is increased secretion of plasminogen activator inhibitor (PAI-1) [Vaughan et al. 1995] . Similarly in rodents, IL-6 synthesis by smooth muscle cells is increased following exposure of these cells to angiotensin II [Schieffer et al. 2000 ]. Production of cytokines from T lymphocytes may result from angiotensin II stimulation of these lymphocytes as seen in animal models of hypertension [Madhur et al. 2010; Guzik et al. 2007 ]. Activation of the RAAS, which stimulates T lymphocytes, can lead to the elevated blood pressure, and this may represent the link between inflammation and hypertension.
Despite the body of experimental data that are supportive of a causal role of inflammation in hypertension, clinical data are limited, especially in high-risk ethnic groups. The purpose of this study was to determine if there are associations of proinflammatory cytokines with high blood pressure and with obesity in a relatively healthy cohort of young adult African Americans without known CVD. Further, the study sought to determine if there was a statistically significant interaction between high blood pressure and obesity that markedly increased plasma levels of inflammatory biomarkers.
Methods
Participants for this study were recruited from urban Philadelphia communities.
Design overview
We conducted an observational cohort study on the impact of hypertension and obesity on CVD risk in healthy young African American adults.
Setting and participants
Participants were recruited in Philadelphia through local advertisements between 2006 and 2009. Inclusions for the enrollment included adults with or without obesity [defined as body mass index (BMI) 30 kg/m 2 ] and/or high blood pressure (HBP, defined as blood pressure 130/ 85 mmHg or on any antihypertensive medications). Exclusions included known diabetes, secondary hypertension, renal disease, CVD, autoimmune disease, thyroid disease, sickle cell disease, eating disorders, and use of steroids. The study protocol was approved by the Institutional Review Board of Thomas Jefferson University. Written informed consent was obtained from each participant.
Study variables
Data on health status, medication use, and health-related behaviors were obtained by self report of each participant. Clinical assessment consisted of BP and anthropometric measurements (height, weight, and waist circumference). BP measurements were obtained from the right arm of each participant following a 10 min rest period in a seated position. Trained research nurses obtained the BP measures. Four separate measurements of systolic BP (SBP) and diastolic BP (DBP) were obtained at each of two separate visits. The average of all measures of SBP and DBP was used as the BP value for each participant.
A fasting blood sample was obtained for plasma glucose, insulin, and lipids. Samples of fasting plasma were also prepared and stored for later assay of cytokines including hsCRP, IL-6, PAI-1, tumor necrosis factor alpha (TNF-a), tumor necrosis factor alpha receptor (TNF-aR) and adiponectin. Plasma glucose concentration was analyzed with the glucose oxidase technique (YS Model 27; Glucostat, Yellow Springs, Ohio, USA). Plasma insulin concentration was determined with a solid phase radioimmunoassay (Coat-a-Count; Diagnostic Products Corp, Los Angeles, California, USA). Coefficients of variation for intra-and inter-assay variability for glucose and insulin assays were less than 5%. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA) [Matthews et al. 1985] . Fasting lipids including total cholesterol, low-density lipoprotein, highdensity lipoprotein (HDL), and triglycerides were measured using the Hitachi 704 standard enzymatic method in the Lipid Laboratory of Thomas Jefferson University. All assays for the cytokines were performed by ELISA in duplicate using commercially available kits. Kits for Adiponectin, IL-6, TNF-a, TNF-aR and hsCRP were obtained from R&D Systems (Minneapolis, Minnesota, USA). The kits for PAI-1 were obtained from Aniara (Mason, Ohio, USA). The coefficient of variation for these assays was consistently less than 10% and mostly less than 6%.
Participants were stratified into four different groups based on BMI and BP status: nonobese normal BP (N-NBP), nonobese high BP (N-HBP), obese normal BP (O-NBP), and obese high BP (O-HBP). Obese was defined as BMI 30 kg/m 2 while nonobese includes both overweight (BMI 25 to < 30 kg/m 2 ) and normal weight (BMI < 25 kg/m 2 ).
Statistical methods
The data were analyzed by categorical and continuous variables. Gender, obesity, HBP, glucose tolerance status, alcohol consumption, and smoking status were the categorical variables. The variables were summarized in terms of counts and percentages. The continuous variables included age, BMI, waist circumference, HOMA, adiponectin, IL-6, PAI-1, TNF-a, TNF-aR, and hsCRP. The distributions of HOMA, adiponectin, IL-6, TNF-a, TNF-aR, and hsCRP were substantially right-skewed and would not be suitable for analysis with ANOVA and regression statistical methods. Natural logarithm transformation of these data made their respective distributions approximately normal and appropriate for parametric analysis. Means calculated on the log scale were antilog transformed to estimate geometric means for summary on the original data scales. As an alternative to standard deviations, we represented the dispersion of the original distributions with their first and third quartiles. For consistency of presentation, PAI-1 has also been summarized by these descriptive statistics. Arithmetic means and standard deviations were used to describe the other continuous variables. To test for differences in means across the BMI/BP groups, unadjusted analysis of variance (ANOVA) F-tests were conducted on continuous variables. Fisher's exact test was used to detect dependencies between categorical variables and BMI/BP group.
Linear regression models were fit to investigate how adiponectin, IL-6, PAI-1, TNF-a, TNF-aR, and hsCRP respectively relate to obesity and HBP after adjusting for age, gender, smoking and alcohol consumption. The regression parameter estimates for the log-transformed dependent variables were anti-log transformed to the original scale after fitting the models and presented as geometric mean ratios (GMRs). Model results are presented for obesity, HBP, or both conditions by linear contrast in terms of expected GMRs with 95% confidence intervals (CIs) or expected differences in the case of PAI-1 which required no log transformation. The significance of an interaction term between obesity and HBP was tested by a 1 degree of freedom likelihood ratio test for each dependent variable model. If interactions were detected, further models with obesity or HBP indicators respectively replaced with continuously measured BMI or SBP were fit to the data and evaluated for the significance of main and interaction terms. The significance level for all tests was set at a ¼ 0.05.
Role of the funding source
The funding agency, Pennsylvania Department of Health, had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Results
A total of 505 young adult African Americans were enrolled in this study. Twenty-one participants were removed from data analysis for either incomplete data, inability to verify reported antihypertensive medication use, or suspected renal disease, defined as urinary albumin excretion (UAE) > 300 mg/g creatinine and/or serum creatinine > 1.5 mg/dl. Data analysis was conducted on 484 study participants with complete data. These participants were stratified into four groups based on their BMI and BP status as described in the methods. Table 1 summarizes the baseline characteristics of the four groups. The obese groups (O-NBP and O-HBP) included more women (70% and 60% respectively), while the nonobese groups (N-NBP and N-HBP) included more men (58% and 72% respectively). Although no known diabetics were enrolled in the study, 9% (n ¼ 45) of participants were found to have diabetes. Insulin resistance, estimated by HOMA, was dependent on BMI/BP status (p < 0.001), with HOMA generally greater among the obese groups compared with the nonobese groups, and highest in the group with both obesity and HBP. Table 2 summarizes the cytokine levels, presented as geometric means and first and third quartiles, for each of the BMI/BP groups. With the exception of TNF-a, there were statistically significant differences between the groups for all of the proinflammatory cytokines. Plasma levels of adiponectin, the anti-inflammatory cytokine, were lower among the obese groups (O-NBP and O-HBP) compared with the nonobese groups (N-NBP and N-HBP) (p < 0.001). The cytokines, IL-6, PAI-1, TNF-aR and hsCRP were all higher in the obese groups (O-NBP and O-HBP) compared with the nonobese groups (N-NBP and N-HBP).
Although, the major influence on the plasma cytokine levels appeared to be related to obesity, further statistical analysis was performed to determine whether there was an independent association with HBP. A linear regression model adjusted for age, gender, smoking, and alcohol consumption was used to examine the relationships of HBP and obesity, independently and together, with each cytokine. Table 3 displays the estimated association of obesity, HBP, and both obesity and HBP together on the various cytokines. Due to the skewed distribution of cytokine measures, the data required log transformation and are presented as expected geometric mean ratios (GMRs). Obesity and HBP together had generally additive associations with the expected GMR for the cytokines. However, there were no statistically significant interactions observed between HBP and obesity for adiponectin, IL-6, TNF-a, TNF-aR, or hsCRP. Therefore the interaction terms were excluded from the models of these cytokines. Obesity alone was associated with a 30% decrease in the expected geometric mean for adiponectin compared with those with a BMI less than 30 kg/m 2 . HBP alone was also associated with a decrease (13%) in the expected geometric mean for adiponectin compared with normal BP. Obesity and HBP together was associated with a 39% decrease in the expected geometric mean for adiponectin compared with the N-NBP group. Similarly, for the proinflammatory cytokines, obesity, independent of blood pressure, was associated with increases in the geometric mean for IL-6 ( + 37%), and TNF-aR ( + 17%). Obesity, independent of blood pressure, was associated with a twofold increase in the expected geometric mean for hsCRP. HBP alone was associated with an increase in the expected geometric mean for TNF-a ( + 20%). However, HBP had no significant association with the expected geometric mean for IL-6 and TNF-aR. HBP alone was associated with a 25% increase in hsCRP. We repeated this analysis with HBP defined as SBP or DBP 140/90 mm Hg or on antihypertensive medication. The results using a higher threshold for HBP were very similar.
PAI-1 did not require log transformation therefore regression parameters for expected mean differences are reported instead of GMRs. A significant negative interaction was detected between HBP and obesity in the model of PAI-1 (12.1 ng/ml, p ¼ 0.03). For HBP alone the expected increase in PAI-1 is 21.47 ng/ml (95% CI 13.5 to 29.5). For obesity alone the expected increase in PAI-1 is 11.2 ng/ml (95% CI 3.1 to 19.2). After taking into account the interaction, the expected increase in mean PAI-1 levels associated with having both conditions was 20.5 ng/ ml (95% CI 12.5 to 28.5) as compared with the N-NBP group. This suggests that when both conditions are present, PAI-1 levels are not as high as would be expected if HBP and obesity were independently and additively associated with PAI-1. To further evaluate this, we first considered the finding that a substantial portion of the N-HBP group were overweight (Table 1) . We then replaced the obesity indicator with continuously measured BMI in the PAI-1 model. The interaction then became nonsignificant (0.53 ng/ml, p ¼ 0.13). The model fit after removing this interaction suggested that PAI-1 was not significantly associated with HBP (p ¼ 0.19), but generally increased by 1 ng/ml per unit of BMI (p < 0.001).
It was notable that a number of participants in the nonobese groups were overweight (BMI > 25 kg/m 2 ). As described above, the results of our previous analysis demonstrated a strong association between obesity and cytokines. Therefore, the cohort was also stratified according to BMI to further determine the relationship between obesity and the cytokines. Figure 1 *These dependent variable data were natural log transformed to correct for skewness in regression models. The coefficient results were antilog transformed and presented as geometric mean ratios which represent multiplicative increases in the dependent variable (e.g. IL-6) associated with the independent variable (e.g. obesity). CI, confidence interval; HBP, high blood pressure; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; TNF, tumor necrosis factor. lower in the severely obese group compared with the normal group (4.0 mg/ml versus 6.2 mg/ml). Plasma IL-6 was significantly related to BMI level (p < 0.001) where higher levels among the severely obese compared with the normal BMI group were observed. Notably, plasma IL-6 levels were similar in the overweight group and the obese group (2.2 pg/ml versus 2.2 pg/ml). PAI-1, TNF-aR and hsCRP were significantly related to BMI level (p < 0.001) and were greater among the obese compared with the nonobese groups. The relationship between TNF-a and BMI was not statistically significant (p ¼ 0.144). Overall, the data demonstrate a decrease in plasma adiponectin levels and increases in proinflammatory cytokines with increasing BMI that began with the overweight level of BMI 25 kg/m 2 .
Discussion
In this study of nearly 500 African American adults we found that HBP and obesity were both independently associated with proinflammatory cytokines and inversely with adiponectin. However, we did not detect a significant interaction between obesity and HBP that was associated with elevated cytokine levels. When present together, HBP and obesity had generally additive associations with proinflammatory cytokines and the anti-inflammatory cytokine adiponectin, except for PAI-1. Further, our analysis demonstrates that, compared with HBP, there is a much stronger association of obesity with plasma levels of proinflammatory cytokines.
The relationship between obesity and inflammation has been well described. Adipose tissue, particularly visceral adiposity, contains large adipocytes that activate inflammatory pathways leading to secretion of cytokines [Brooks et al. 2010; Hozawa et al. 2007 ]. Of the proinflammatory cytokines, CRP is the most studied, and has an established association with CVD risk.
Interventions that reduce plasma CRP levels, such as statin therapy in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, resulted in a reduction in cardiovascular events .
Evidence for the link between obesity and CRP is seen in studies such as that reported by Ziccardi and colleagues, who reported that a reduction in fat mass in postmenopausal women with obesity was associated with decreases in CRP [Ziccardi et al. 2002] . In another study from Israel, Aronson and colleagues examined CRP on nearly 2000 middle-aged patients with metabolic syndrome [Aronson et al. 2004] . From their data analysis, the authors determined that of the five metabolic syndrome components, BMI was the strongest factor determining CRP [Aronson et al. 2004] . Similarly, we found that hsCRP was higher among obese, compared with nonobese participants, and CRP was more strongly associated with BMI than with HBP.
The association between CRP and obesity is most often described in people with a BMI 30 kg/m 2 . Previous studies have noted that metabolic abnormalities are not uniformly present among people with obesity [Wildman et al. 2008 ]. These 'metabolically healthy' people with obesity typically have lower fasting insulin, plasma triglycerides, hsCRP and higher HDL compared with other people with obesity [Karelis et al. 2005] . Large epidemiologic studies have also found higher mortality rates among overweight whites compared with overweight African Americans, again suggesting that BMI is only a risk factor above 30 kg/m 2 in African Americans [Calle et al. 1999; Durazo-Arvizu et al. 1998 ]. However, the results from our study demonstrate rising cytokine levels among those who were overweight. In addition, cytokine levels, particularly IL-6 and TNF-a (data not shown), among the overweight group were similar to the obese groups. On the one hand, these findings support the notion that defining obesity according to BMI alone has limitations, and that definitions which include waist circumference or a determination of percentage of body fat may better reflect peoples' CVD risk profile [Shea et al. 2010 ]. On the other hand, our data suggest that the risks related to inflammation increase with BMI > 25 kg/m 2 .
It is unclear from clinical studies whether mediators of inflammation play a causal role in the development of hypertension or are a result of longstanding elevated blood pressure. We did find a modest relationship between blood pressure status and proinflammatory cytokines. Similarly, in a cross-sectional analysis of data on over 500 men from the Physicians Health Study, Chae and colleagues reported a significant association of plasma IL-6 with systolic and diastolic blood pressure level [Chae et al. 2001] . Following adjustment for age, BMI, smoking and other variables, only SBP remained significantly associated with plasma IL-6 levels [Chae et al. 2001 ].
Our results are also similar to data reported on the Multi-Ethnic Study of Atherosclerosis (MESA). In the MESA prospective study, IL-6 and CRP were measured at baseline on normotensive middle-aged adults and analyzed as predictors of incident hypertension within 5 years of follow up. Among those who developed hypertension, baseline IL-6 and CRP were higher compared with those who remained normotensive. However, this association was attenuated following adjustment for BMI [Lakoski et al. 2010] . Similarly, the parameters of inflammation examined in our cohort were largely driven by overweight and obesity.
We detected a negative interaction between obesity and HBP when predicting PAI-1. This result reflects the data presented for PAI-1 in Table 2 as PAI-1 levels in the O-HBP group were not as high as would be expected if HBP and obesity were additively associated with PAI-1. BMI has a strong and essentially linear association with PAI-1 (Figure 1) , while BP appears to have a relatively weak association (data not shown). The interaction could be explained in part by the imbalance of overweight participants in the N-HBP group (Table 1) . After further analysis, we concluded that the association of increased BMI to HBP was a false interaction. After replacing the obesity indicator with BMI in the PAI-1 models, the interaction and HBP terms were no longer significant in predicting PAI-1 levels.
This study is limited by the fact that only African Americans were examined. Therefore, the results may not be generalizable to other racial/ethnic groups. Additionally, the cross-sectional design only allows us to demonstrate the associations between obesity, HBP, and biomarkers of inflammation, and we cannot draw conclusions related to cause and effect.
Although we found only a modest association of inflammation with hypertension in our cross-sectional study, it is possible that obesity-mediated inflammation could contribute to hypertension, especially because our cohort is relatively young. A prospective study on the normotensive people with obesity could provide insights on the extent to which inflammation contributes to incident hypertension. While weight loss among people with obesity would likely lower both blood pressure level and also the circulating levels of the inflammatory cytokines, clinical trials designed to test the effects of novel antiinflammatory treatments on blood pressure would clarify the issue and potentially lend more support to the theory that inflammation is directly involved in the pathogenesis of hypertension.
Obesity and HBP are each independently associated with levels of proinflammatory cytokines, including hsCRP, IL-6, TNF-a, and TNF-aR. When both conditions are present the association with cytokine levels are additive. Obesity appears to have the predominant association with cytokine levels. Cytokine levels, although greatest among people with obesity, began to increase among the overweight (25 BMI < 30 kg/m 2 ). These findings suggest that the risk of CVD among overweight African Americans may be underestimated. Additionally, interventions to reduce obesity-related inflammation may impact CVD outcomes.
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